Kura Oncology Stock Forecast, Price & News

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology or view top-rated stocks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Kura Oncology?

Kura Oncology saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 7,160,000 shares, a decline of 21.9% from the August 31st total of 9,170,000 shares. Based on an average daily trading volume, of 670,400 shares, the short-interest ratio is presently 10.7 days. Approximately 11.7% of the shares of the stock are short sold.
View Kura Oncology's Short Interest.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.
View Kura Oncology's earnings history.

How has Kura Oncology's stock price been impacted by Coronavirus?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KURA stock has increased by 72.8% and is now trading at $16.68.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KURA?

7 analysts have issued 12 month price targets for Kura Oncology's stock. Their forecasts range from $34.00 to $56.00. On average, they anticipate Kura Oncology's stock price to reach $43.71 in the next year. This suggests a possible upside of 162.1% from the stock's current price.
View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:

• Troy E. Wilson, Chairman, President & Chief Executive Officer
• Kathleen Ford, Chief Operating Officer
• Marc Edward Grasso, Chief Financial & Business Officer
• Stephen Dale, Chief Medical Officer
• Mollie Leoni, Vice President-Clinical Development

Who are some of Kura Oncology's key competitors?

Some companies that are related to Kura Oncology include TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Arvinas (ARVN), Karuna Therapeutics (KRTX), Aurinia Pharmaceuticals (AUPH), Schrödinger (SDGR), Cryoport (CYRX), Intra-Cellular Therapies (ITCI), Zentalis Pharmaceuticals (ZNTL), Reata Pharmaceuticals (RETA), Lyell Immunopharma (LYEL), Arena Pharmaceuticals (ARNA), Galapagos (GLPG), Hypera (HYPMY) and Insmed (INSM).
View all of KURA's competitors.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.26%) and Phoenix Holdings Ltd. (0.26%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

Which institutional investors are buying Kura Oncology stock?

KURA stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Phoenix Holdings Ltd..
View insider buying and selling activity for Kura Oncology or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $16.68.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $1.11 billion. The company earns $-89.63 million in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 89 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 500-8800 or via email at [email protected].